Lower vancomycin serum trough concentrations might not be the answer

Pediatric Infectious Disease Journal

Volumn 32, Issue 12, 2013, Pages 1403-1404

  Hahn, Andrea ^a   Vinks, Alexander A ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VANCOMYCIN; ANTIINFECTIVE AGENT;

AREA UNDER THE CURVE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; HUMAN; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; BLOOD; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; HUMANS; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84891675728     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000003     Document Type: Letter

References (5)

1. Frymoyer A, Guglielmo BJ, Hersh AL. desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections. Pediatr Infect Dis J. 2013;32:1077-1079.
2. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methi-cillin- resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis. 2011;52:285-292.
3. Lamarre P, Lebel D, Ducharme M P. A population pharmacokinetic model for vancomycin in pediatric patients and its predictive value in a naive population. Antimicrob Agents Chemother. 2000;44:278-282.
4. Jelliffe RW, Schumitzky A, Bayard D, et al. Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals. Clin Pharmacokinet. 1998;34:57-77.
5. Kullar R, Davis SL, Levine DP, et al. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52:975-981.